Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company UpdatesGlobeNewsWire • 07/31/25
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?Benzinga • 07/30/25
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'Seeking Alpha • 07/18/25
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?Zacks Investment Research • 06/25/25
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology CongressGlobeNewsWire • 06/15/25
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%Zacks Investment Research • 06/04/25
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy StudyZacks Investment Research • 05/30/25
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On CourseBenzinga • 05/29/25
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 05/23/25
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual MeetingGlobeNewsWire • 05/18/25
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?Zacks Investment Research • 05/15/25
Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)Seeking Alpha • 05/14/25
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)Seeking Alpha • 05/12/25
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock UpZacks Investment Research • 05/09/25
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/08/25
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline CatalystsSeeking Alpha • 05/05/25
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to DeclineZacks Investment Research • 05/01/25